Advances in the use of therapeutic pheresis for the management of rheumatic diseases.
Twenty-two patients with rheumatoid arthritis, 3 with seronegative juvenile rheumatoid arthritis, 4 with systemic lupus erythematosus, and 4 with psoriatic arthritis have undergone therapeutic pheresis at our institution over the last 3 yr. Lymphoplasmapheresis appears to be the most effective form of pheresis in treating rheumatoid arthritis. After achieving a remission with 20 treatments performed in 11 wk, a flare may be preventable by pheresing patients 3 times a week every 6 wk provided the patient is on a concomitant, long-acting agent. Therapeutic pheresis has been disappointing in seronegative juvenile rheumatoid arthritis. Life-threatening complications of systemic lupus erythematosus may respond dramatically to pheresis. In treating less severe disease on a long-term basis, pheresis has demonstrated excellent steroid sparing properties. Nonspondylytic psoriatic arthritis responds slowly to pheresis, but arthritic remissions may be prolonged, even though skin response is variable. Experience in the use of pheresis for treating these diseases has allowed for the development of criteria for deciding whether to institute such therapy as an adjunct to more standard modes of treatment for individual patients. Also, a variety of "technical" factors can influence the outcome of therapy, and these must be managed appropriately. Therapeutic pheresis is a promising tool for investigating and treating rheumatic diseases.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001168:Arthritis / Q000628:therapy*; D001171:Arthritis, Juvenile / Q000628:therapy; D001172:Arthritis, Rheumatoid / Q000628:therapy; D003095:Collagen Diseases / Q000097:blood / Q000628:therapy*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000295:instrumentation / Q000379:methods*
D000893:Anti-Inflammatory Agents